-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
FEBRUARY 12, 2021 /--- -- A study led by researchers at Baylor College of Medicine has revealed new effects of steroid-like co-activation factor 3 (SRC-3 / NCOA3), which is essential for steroid hormone function and is a prognostic marker for invasive breast and other cancers.
(Photo: www.pixabay.com) the team found that SRC-3 also regulates the body's immune activity by inhibiting the function of other immune cells, including cancer-related immune cells.
study, published in Scientific Reports, showed that Treg, which eliminates SRC-3 function, does not inhibit the activity of other immune cells.
the authors predict that their findings could help fight cancer by developing new ways to inhibit Tregs activity.
Bert O'Malley, a professor of molecular and cellular biology at Baylor University, said: "Treg played an important role by inhibiting immune activity that could impair the body.
, for example, Treg is essential to prevent autoimmunity, an immune response to normal human tissue that can lead to serious diseases.
" in addition, breast cancer and other types of tumors include soaked immune cells, which can help control tumor growth, or, on the other hand, provide local immunosuppression that is beneficial to tumor growth.
Treg immersion has been experimentally demonstrated in breast tumor biopsies, and is associated with poor prognostics and reduced survival in patients.
"SRC-3 is known for its role in cancer formation and proliferation, but we want to know what role it will play in immune T cells," said co-first author Dr. Bryan Nikolai, a senior scientist at Cooper Genomics and an adjunct assistant professor of molecular and cell biology at Baylor University.
's review of biometric data shows that SRC-3 is highly expressed in Tregs, which encourages us to do research.
continue this research.
""Our experiments have shown that SRC-3 is a significant collection in both rats and human Treg.
by using the small molecule inhibitor SI-2, Tregs significantly reduced its ability to inhibit the activity of other immune cells.
"O'Malley Laboratory has previously demonstrated that SI-2 eliminates SRC-3 from breast cancer cells, therefore inhibiting tumor growth in breast cancer mouse models."
now we know that SRC-3 also plays a key role in the immune system, " he said.
O'Malley, a member of the Dan L Duncan Comprehensive Cancer Center in Baylor, said: "There is a lot of interest in finding ways to suppress Treg, which suppresses the immune system.
"We are pleased that the use of small molecule inhibitors may lead to promising therapies in the future."
if we can eliminate the inhibition of small molecule inhibitors to Tregs' anti-cancer immune response, then the immune system will be able to go to the tumor.
(Bioon.com) Source: SRC-3 is novel regulator of human immune T regulatory cells Original source: Bryan C. Nikolai et al, Steroid receptor coactivator 3 (SRC-3/AIB1) is enriched and functional in mouse and human Tregs, Scientific Reports (2021). DOI: 10.1038/s41598-021-82945-3